|
Survival outcomes with
the use of surgery in limited-stage small cell lung
cancer. Should its role be re-evaluated?
|
| David Schreiber, MD
Cancer 2010. Published Online: Jan 15 2010
|
Department of Radiation Oncology,
State University of New York Downstate Medical Center,
Brooklyn, New York
|
BACKGROUND: |
| Although chemotherapy and radiation
therapy currently are recommended in
limited-stage small
cell lung cancer (L-SCLC), several small series have
reported favorable survival outcomes in patients who
underwent surgical resection. The authors of this report
used a US population-based database to determine survival
outcomes of patients who underwent surgery. |
| |
| The Surveillance, Epidemiology, and
End Results (SEER) registry was used to identify patients
who were diagnosed with L-SCLC between 1988 and 2002 coded
by SEER as localized disease (T1-T2Nx-N0) or regional
disease (T3-T4Nx-N0). Kaplan-Meier and Cox regression
analyses were used to compare overall survival (OS) for all
patients. |
RESULTS: |
| In total, 14,179 patients were
identified, including
863 patients who
underwent surgical resection. Surgery was associated
more commonly with T1/T2 disease.
Surgery was
associated with improved survival for both localized disease
and regional disease with improvements in median survival
from 15 months to 42 months and from 12 months to 22 months
respectively.
Lobectomy was associated with the best
outcome. Patients with localized disease who underwent
lobectomy with had a median survival of 65 months and a
5-year OS rate of 52.6%; whereas patients who had regional
disease had a median survival of 25 months and a 5-year OS
rate of 31.8%. On multivariate analysis, the benefit
of surgery varied in a time-dependant fashion. However, the
benefit of lobectomy remained across all time intervals. |
CONCLUSIONS: |
| The use of surgery, and particularly
lobectomy, in selected patients with L-SCLC was associated
with improved survival outcomes. Future prospective studies
should consider the role of surgery as part of the
multimodality management of this disease. |
|